ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.

Company Overview

Founded in 1999, Allele Biotechnology and Pharmaceuticals is a privately held company that examines the mechanisms of biological processes to develop products and technologies for biomedical research and therapy development. The company utilizes proprietary nonintegrating cellular reprogramming methods to enable cell therapy and drug discovery, including GMP-grade human iPSCs and their derivatives, human and nonhuman primate iPSCs, and differentiated cell types. Having additional expertise in genome modification and cell-based sensors/reporters, the company provides advanced cell and assay development solutions. The company has also developed a wide variety of reagents, including luciferase assay substrates, fluorescent proteins, genotyping kits, and camelid antibodies.

Allele provides custom iPS generation services. Over the years, Allele Biotech has worked on biological advancements that have been at the forefront of molecular biology research, such as iPSCs and genome editing. In 2015, the company established a cGMP facility in San Diego to further the clinical development of iPSC-based cell therapy.

Allele Biotechnology has developed and patented (USPTO 10119150, 10155929) its proprietary iPSC reprogramming and differentiation methods that are based on nonintegrating mRNA technology to enable the clinical use of iPSCs. mRNA-based reprogramming allows for precise stoichiometric control of reagents and yields robust stem cells with unparalleled efficiency.

Allele Biotechnology is actively involved in combating the COVID-19 global pandemic. Starting in January 2020, the company’s dedicated research team initiated projects utilizing its cutting-edge iPSC and nanoantibody platforms to create impactful diagnostics and therapeutics, while its bioinformatics team analyzed the initial 6,000 SARS-CoV-2 genomes by April, 2020 One of the effective approaches for COVID-19 that is being widely explored is immunization. Allele Biotechnology took a different approach from most and worked on developing specially treated iPSC-derived vesicles presenting COVID-19 specific antigens via mRNA expression.

Company's Business Segments

• Products : The company generates revenue from different research tools such as Genotyping, mRNA, Fluorescent Proteins, nAb - Nanoantibodies.